Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism

Oncotarget

Volumn 6, Issue 27, 2015, Pages 24148-24162

  Chen, Guo Qing ^a,b   Tang, Cheng Fang ^a,c   Shi, Xiao Ke ^a   Lin, Cheng Yuan ^a   Fatima, Sarwat ^a   Pan, Xiao Hua ^d   Yang, Da Jian ^b   Zhang, Ge ^a   Lu, Ai Ping ^a   Lin, Shu Hai ^a   Bian, Zhao Xiang ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b CHONGQING ACADEMY OF CHINESE MATERIA MEDICA   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

Akt mTORC1; Anticancer activity; Colorectal cancer; Glucose metabolism; Halofuginone

Indexed keywords

GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 1; HALOFUGINONE; HEXOKINASE; HEXOKINASE 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PENTOSE PHOSPHATE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; HEXOKINASE 2, MOUSE; LIPID; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PIPERIDINE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR; QUINAZOLINONE DERIVATIVE; SLC2A1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLIC REGULATION; METABOLOMICS; MOUSE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; CHINESE MEDICINE; COLORECTAL NEOPLASMS; HCT 116 CELL LINE; METABOLISM; NUDE MOUSE; PENTOSE PHOSPHATE CYCLE; TUMOR CELL LINE; TUNEL ASSAY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HCT116 CELLS; HEXOKINASE; HUMANS; IN SITU NICK-END LABELING; LIPIDS; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPROTEIN COMPLEXES; PENTOSE PHOSPHATE PATHWAY; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINONES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84943391216     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4376     Document Type: Article

References (49)

1. Shin A, Jung KW and Won YJ. Colorectal cancer mortality in Hong Kong of China, Japan, South Korea, and Singapore. World J Gastroenterol. 2013;19:979-983.
2. Markowitz SD and Bertagnolli MM. Molecular origins of cancer:Molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-2460.
3. Koseoglu S, Lu Z, Kumar C, Kirschmeier P and Zou J. AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. Cancer Biol Ther. 2007;6:755-762.
4. Shaw RJ and Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424-430.
5. Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, Xu MH, Chen GQ, Han ZG and Fang JY. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol. 2009;16:2617-2628.
6. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A. 2011;108:4129-4134.
7. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO and Manning BD. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39:171-183.
8. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, Sellers R and Ghaffari S. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. EMBO J. 2010;29:4118-4131.
9. Maiese K, Chong ZZ, Shang YC and Wang S. mTOR:on target for novel therapeutic strategies in the nervous system. Trends Mol Med. 2013;19:51-60.
10. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-314.
11. Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect:the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033.
12. Jin ML, Park SY, Kim YH, Park G and Lee SJ. Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9. Int J Oncol. 2014;44:309-318.
13. de Figueiredo-Pontes LL, Assis PA, Santana-Lemos BA, Jacomo RH, Lima AS, Garcia AB, Thome CH, Araujo AG, Panepucci RA, Zago MA, Nagler A, Falcao RP and Rego EM. Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. PLoS One. 2011; 6:e26713.
14. Pines M and Nagler A. Halofuginone:a novel antifibrotic therapy. Gen Pharmacol. 1998;30:445-450.
15. Elkin M, Ariel I, Miao HQ, Nagler A, Pines M, de-Groot N, Hochberg A and Vlodavsky I. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res. 1999;59:4111-4118.
16. Elkin M, Reich R, Nagler A, Aingorn E, Pines M, de-Groot N, Hochberg A and Vlodavsky I. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res. 1999;5:1982-1988.
17. Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, Eshhar Z and Pines M. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate. 2002;51:73-83.
18. Nagler A, Ohana M, Shibolet O, Shapira MY, Alper R, Vlodavsky I, Pines M and Ilan Y. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer. 2004;40:1397-1403.
19. Juarez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A and Guise TA. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res. 2012;72:6247-6256.
20. Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, Rhule-Smith A, Lefebvre RE, Unutmaz D, Mazitschek R, Waldner H, Whitman M, Keller T and Rao A. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science. 2009;324:1334-1338.
21. Carlson TJ, Pellerin A, Djuretic IM, Trivigno C, Koralov SB, Rao A and Sundrud MS. Halofuginone-induced amino acid starvation regulates Stat3-dependent Th17 effector function and reduces established autoimmune inflammation. J Immunol. 2014;192:2167-2176.
22. Sabharwal SS and Schumacker PT. Mitochondrial ROS in cancer:initiators, amplifiers or an Achilles' heel? Nat Rev Cancer. 2014;14:709-721.
23. Roberts DJ and Miyamoto S. Hexokinase II integrates energy metabolism and cellular protection:Akting on mitochondria and TORCing to autophagy. Cell Death Differ. 2015;22:248-257.
24. Francipane MG and Lagasse E. mTOR pathway in colorectal cancer:an update. Oncotarget. 2014;5:49-66.
25. Jin ML, Park SY, Kim YH, Park G and Lee SJ. Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9. International Journal of Oncology. 2014;44:309-318.
26. Harris G and Schaefer KL. Reactive oxygen species induced by the compound bisphenol-a-diglycidylether cause senescence and apoptosis in colorectal cancer cell lines regardless of MDR1 or p53 status. Gastroenterology. 2008; 134:A743-A743.
27. Shin SW, Seo CY, Han H, Han JY, Jeong JS, Kwak JY and Park JI. 15d-PGJ(2) Induces Apoptosis by Reactive Oxygen Species-mediated Inactivation of Akt in Leukemia and Colorectal Cancer Cells and Shows In vivo Antitumor Activity. Clinical Cancer Research. 2009;15:5414-5425.
28. Zhou J, Li P, Xue XF, He SB, Kuang YT, Zhao H, Chen SJ, Zhi QM and Guo XB. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species. Toxicology Letters. 2013; 222:139-145.
29. Jeong JB, Choi J, Baek SJ and Lee SH. Reactive oxygen species mediate tolfenamic acid-induced apoptosis in human colorectal cancer cells. Archives of Biochemistry and Biophysics. 2013;537:168-175.
30. Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life. 2012;64:362-369.
31. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M and Yang X. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol. 2011;13:310-316.
32. Kim DD and Eng C. The promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opin Investig Drugs. 2012;21:1775-1788.
33. Roberts DJ and Miyamoto S. Hexokinase II integrates energy metabolism and cellular protection:Akting on mitochondria and TORCing to autophagy. Cell Death Differ. 2015;22:248-57.
34. Feng Z and Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 2010;20:427-434.
35. Xu Y, Miriyala S, Fang F, Bakthavatchalu V, Noel T, Schell DM, Wang C, St Clair WH and St Clair DK. Manganese superoxide dismutase deficiency triggers mitochondrial uncoupling and the Warburg effect. Oncogene. 2014.
36. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M and Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22:66-79.
37. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M and Yang X. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol. 2013;15:991-1000.
38. Ellis BC, Graham LD and Molloy PL. CRNDE, a long noncoding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta. 2014;1843:372-386.
39. Wei Z, Cui L, Mei Z, Liu M and Zhang D. miR-181a mediates metabolic shift in colon cancer cells via the PTEN/AKT pathway. FEBS Lett. 2014;588:1773-1779.
40. Wang L, Xiong H, Wu F, Zhang Y, Wang J, Zhao L, Guo X, Chang LJ, Zhang Y, You MJ, Koochekpour S, Saleem M, Huang H, Lu J and Deng Y. Hexokinase 2-mediated Warburg effect is required for PTEN-and p53-deficiencydriven prostate cancer growth. Cell Rep. 2014;8:1461-1474.
41. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey RB and Hay N. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24:213-228.
42. Qi W, Fitchev PS, Cornwell ML, Greenberg J, Cabe M, Weber CR, Roy HK, Crawford SE and Savkovic SD. FOXO3 growth inhibition of colonic cells is dependent on intraepithelial lipid droplet density. J Biol Chem. 2013; 288:16274-16281.
43. Bhalla K, Hwang BJ, Dewi RE, Ou L, Twaddel W, Fang HB, Vafai SB, Vazquez F, Puigserver P, Boros L and Girnun GD. PGC1alpha promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res. 2011;71:6888-6898.
44. Zaytseva YY, Elliott VA, Rychahou P, Mustain WC, Kim JT, Valentino J, Gao T, O'Connor KL, Neltner JM, Lee EY, Weiss HL and Evers BM. Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer. Carcinogenesis. 2014; 35:1341-1351.
45. Tomek K, Wagner R, Varga F, Singer CF, Karlic H and Grunt TW. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol Cancer Res. 2011;9:1767-1779.
46. Bajer MM, Kunze MM, Blees JS, Bokesch HR, Chen H, Brauss TF, Dong Z, Gustafson KR, Biondi RM, Henrich CJ, McMahon JB, Colburn NH, Schmid T and Brune B. Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor. Biochem Pharmacol. 2014; 88:313-321.
47. Lamming DW and Sabatini DM. A Central role for mTOR in lipid homeostasis. Cell Metab. 2013;18:465-469.
48. Roffe S, Hagai Y, Pines M and Halevy O. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells:effect on myotube fusion. Exp Cell Res. 2010;316:1061-1069.
49. Wang H and Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med. 1999;27:612-616.